UNSPSC 51171911: Sucralfate

This classification denotes a radioprotective agent and cytoprotective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XX73205DH5. European Medicines Agency schedules Sucralfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04613MIG. Sucralfate generally arises in the molecular formula C12H54AL16O75S8.

The term SUCRALFATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, no. 11 1970, list 10.) SUCRALFATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sucralfate under HS 29400000 and SITC 51692. As of Q4 2014, SUCRALFATE remains the US FDA Preferred Term for this commodity. Sucralfate bears US NLM identifiers UMLS ID C0038633 and NCI Concept Code C848.

UNSPSC 51171911 Sucralfate is a Commodity code representing pharmaceutical products actively procured by state agencies and county departments. State and local governments buying under this code seek branded and generic pharmaceuticals through cooperative purchasing arrangements, direct vendor contracts with state health agencies, and county criminal justice procurement. The scope encompasses supply chain compliance including FDA certification, cGMP manufacturing practices, Drug Supply Chain Security Act adherence, and electronic data interchange capability. Vendors must maintain relationships with authorized wholesalers, manage product inventory with minimum shelf-life requirements, and support pricing models ranging from net-price to WAC-minus structures with administrative fees.

Recent solicitation activity spans multiple states and issuing bodies. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to explore direct-to-manufacturer prescription programs and vendor capabilities for future state pharmacy benefit procurement, signaling upstream market activity. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services (due July 23, 2026), a criminal justice application showing demand for pharmacy and testing services at the county level. Geographic concentration appears heaviest in Texas and Minnesota, with MMCAP's multi-state cooperative model extending procurement influence across participating jurisdictions. Contract values in recent opportunities range from estimated $600,000 for Collin County's two-year term to unspecified allocations through MMCAP's multi-award structure; vendors typically absorb freight, delivery, insurance, and administrative costs with performance penalties for compliance failures.